帕博利珠单抗治疗晚期黑色素瘤患者的KEYNOTE-001研究五年生存结局
KEYNOTE-001 Ib期研究纳入655例晚期黑色素瘤患者,接受帕博利珠单抗2 mg/kg每3周、10 mg/kg每3周或10 mg/kg每2周治疗,中位随访55个月。全部患者估计5年OS率为34%、初治患者为41%;全部患者中位OS为23.8个月(95% CI,20.2-30.4),初治患者为38.6个月(95% CI,27.2-未达到)。
要点
- 全部患者估计5年OS率为34%,初治患者为41%。
- 全部患者中位OS为23.8个月(95% CI,20.2-30.4),初治患者为38.6个月(95% CI,27.2-未达到)。
- 86%患者发生治疗相关不良事件,7.8%因此停药,17%发生3/4级治疗相关不良事件。
核心结论
- 该KEYNOTE-001五年分析是帕博利珠单抗迄今最长的随访,证实其在晚期黑色素瘤中具有持久的抗肿瘤活性和耐受性。
研究设计与样本
- Ib期KEYNOTE-001研究(NCT01295827),纳入655例晚期黑色素瘤患者。
- 患者年龄≥18岁,为经治或初治的晚期/转移性黑色素瘤。
- 帕博利珠单抗给药方案为2 mg/kg每3周、10 mg/kg每3周或10 mg/kg每2周,直至疾病进展、不可耐受毒性或患者/研究者决定退出。
- 采用Kaplan-Meier法估计总生存(OS)和无进展生存(PFS)。
- 客观缓解率和PFS基于研究者评估的免疫相关疗效标准(数据截止2017年9月1日)。
主要发现
- 中位随访55个月;全部患者估计5年OS率为34%,初治患者为41%。
- 全部患者中位OS为23.8个月(95% CI,20.2-30.4),初治患者为38.6个月(95% CI,27.2-未达到)。
- 全部患者估计5年PFS率为21%,初治患者为29%;全部患者中位PFS为8.3个月(95% CI,5.8-11.1),初治患者为16.9个月(95% CI,9.3-35.5)。
- 中位缓解持续时间未达到;数据截止时,全部患者中73%的缓解和初治患者中82%的缓解仍在持续;最长缓解在66个月时仍在持续。
- 4例患者(均有既往完全缓解(CR))在观察期间疾病进展后接受第二疗程帕博利珠单抗,其中1例达到CR、1例达到部分缓解(均在数据截止后)。
关键数值与推荐
- 治疗相关不良事件发生于86%的患者,导致7.8%的患者停止研究;17%的患者发生3/4级治疗相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, NCT01295827.
引用
- Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019. PMID: 30715153. doi:10.1093/annonc/mdz011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。